C5b-9 Antikörper
Kurzübersicht für C5b-9 Antikörper (ABIN8065530)
Target
Alle C5b-9 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Güteklasse
Klon
-
-
Verwendungszweck
- Anti-Complement C5b-9 Antibody
-
Spezifität
- DIA 011-01 binds both membrane-bound MAC (active) and fluid-phase SC5b-9 complexes (inactive). (1) DIA 011-01 binds to a neoepitope exposed on C9
-
Homologie
- Horse,Human,Non-Human Primate,and Pig
-
Aufreinigung
- Protein A or Protein G purified
-
Immunogen
- Purified C5b-9
-
Isotyp
- IgG2a, kappa
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- 0.01 M phosphate buffer, pH 7.4, with 0.14 M NaCl and 15 mM sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- 2-8°C without exposure to light
-
Haltbarkeit
- 12 months
-
-
- C5b-9 (Terminal Complement Complex C5b-9 (C5b-9))
-
Andere Bezeichnung
- Complement C5b-9
-
Hintergrund
- C5, C5D, C5a, C5b, CPAMD4, ECLZB, complement C5, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4, C5a anaphylatoxin, anaphylatoxin C5a analog, complement component 5, prepro-C5,Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:6554279). Activated downstream of classical, alternative, lectin and GZMK complement pathways (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:39914456, PubMed:39814882, PubMed:6554279). Complement C5b Component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis (PubMed:26841837, PubMed:27052168, PubMed:30552328, PubMed:30643019). Complement C5b is generated following cleavage by C5 convertase and initiates formation of the MAC complex: C5b binds sequentially C6, C7, C8 and multiple copies of the pore-forming subunit C9 (PubMed:30552328, PubMed:30643019). During MAC complex assembly, the C5b6 subcomplex, composed of complement C5b and C6, associates with the outer leaflet of target cell membrane, reducing the energy for membrane bending (PubMed:30552328, PubMed:32569291).,C5, C6, C7, C8, C9,C5b-9 is also known as the terminal complement complex (TCC). The TCC consists of C5b, C6, C7, C8 and C9 and forms the membrane attack complex (MAC) as well as the non-lytic fluid-phase SC5b-9 complex (with protein S). The MAC forms channels in target cell membranes leading to cell lysis by osmotic leakage. The complexes contain neoantigens that are absent from the individual native components from which they are formed and DIA 011-01 is directed against a neoepitope exposed on C9 when incorporated into the TCC.
-
Gen-ID
- 727
-
UniProt
- P01031, P13671, P06681, P07357, P07358, P07360, P02749
Target
-